Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.

A hemostatic material, a preparation method thereof, and a pharmaceutical composition containing the same are introduced. The hemostatic material includes 200 to 1600 parts by weight of water-insoluble gelatin and 100 to 1000 parts by weight of hydrating material. The preparation method for the hemostatic material includes the steps of (a) providing 200 to 1600 parts by weight of water-insoluble gelatin and 100 to 1000 parts by weight of hydrating material; and (b) combining the water-insoluble gelatin with the hydrating material to form a hemostatic material. The pharmaceutical composition includes an aforementioned hemostatic material and active pharmaceutical ingredients. Through the aforementioned hemostatic material, hemostatic products can increase the blood absorption capacity.

The present invention relates to an AhR agonist for use in combination with at least one immune checkpoint modulator in the treatment of cancer. The present invention also encompasses product containing an AhR agonist and at least one immune checkpoint modulator as defined in any one of the preceding, claims, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.

The present invention relates to a method for treating hyperpigmentary skin disorder. By using normal human melanocytes (NHMs) and normal human keratinocytes (NHKs), which are infected with CLEC12B siRNA/shRNA/RNAi lentiviral particles, inventors have showed that decreasing CLEC12B expression significantly reduce the transfer of melanin to the keratinocytes. These results demonstrate that CLEC12B is specifically expressed in the skin by melanocytes and plays a key role in the transfer or melanosomes to the keratinocytes. Accordingly, the invention relates to a method for treating hyperpigmentary skin disorder in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a CLEC12B antagonist, wherein CLEC12B antagonist is polypeptide, more particularly a decoy.

The present invention relates to compositions and methods for treating cancer. The invention makes use of peptides, nucleic acids encoding such peptides, and cells expressing such peptides, where the peptide comprises a tumor-associated carbohydrate antigen (TACA)-binding domain.

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.

A method, device and system for ultrasonic delivery and attachment of ligand-receptor based drugs and/or drug carriers and/or image enhancing contrast agents utilizing catch and slip bond mechanisms in a targeted part(s) of the human or animal (patient) body or organs or tissue is described and disclosed. The system includes an acoustic power source coupled to an acoustic transducer with the acoustic transducer placed upon a patient's delivery zone. The acoustic transducer transmits an acoustic field to the target drug delivery and/or imaging zone. A detection probe and/or a probe of an imaging system are placed over or within said delivery zone and the probe is coupled to a sensing/imaging system. A control computer that controls power and wave shape of the acoustic signal generated into the acoustic filed by the acoustic power source and receives data from the sensing/imaging system. This system utilizes catch and slip bonds for the delivery of drugs and/or drug carriers and/or image enhancing contrast agents. Placing an acoustic transducer over a delivery zone having ligand-receptor based drugs and/or drug carriers and/or image enhancing contrast agents. The method includes coupling an acoustic power source to said acoustic power source and installing a probe within or over said delivery zone. The probe is coupled to a sensing/imaging system. A control computer is used to control a power and a wave shape of the acoustic field generated by said acoustic transducer. The method uses a catch and slip bonds within said acoustic field to deliver ligand-receptor based drugs and/or drug carriers and/or image enhancing contrast.

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.